N(5)-ethyl-L-glutamineWhat was measured
Measured, with no finding
753 endpoints
Show what was measuredHide what was measured
heart rate response to acute stress task
decreases
L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition
PMID 16930802 · one of two readings recorded this
salivary immunoglobulin A response to acute stress task
decreases
L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition
PMID 16930802 · one of two readings recorded this
salivary immunoglobulin A (s-IgA) response and heart rate response to a mental arithmetic acute stress task
decreases
Not recorded as a finding: the paper never states the instrument the node requires
The results showed that L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition.
PMID 16930802 · one of two readings recorded this
salivary immunoglobulin A (s-IgA) response and heart rate response to a mental arithmetic stress task; assay not stated in the abstract
decreases
Not recorded as a finding: the paper never states the instrument the node requires
The results showed that L-Theanine intake resulted in a reduction in the heart rate (HR) and salivary immunoglobulin A (s-IgA) responses to an acute stress task relative to the placebo control condition.
PMID 16930802 · one of two readings recorded this
sympathetic nervous activation (heart rate variability analysis)
decreases
analyses of heart rate variability indicated that the reductions in HR and s-IgA were likely attributable to an attenuation of sympathetic nervous activation
PMID 16930802 · one of two readings recorded this
EEG alpha activity in resting healthy participants with eyes closed, at baseline and 45 to 105 minutes after 50mg L-theanine or placebo
increases
Not recorded as a finding: this platform holds no node for the endpoint
There was a greater increase in alpha activity across time in the L-theanine condition (relative to placebo (p+0.05).
PMID 18296328 · one of two readings recorded this
EEG alpha activity
increases
There was a greater increase in alpha activity across time in the L-theanine condition
PMID 18296328 · one of two readings recorded this
EEG alpha activity
increases
A second study replicated this effect in participants engaged in passive activity
PMID 18296328 · one of two readings recorded this
EEG alpha frequency band activity, resting eyes closed, at baseline and 45, 60, 75, 90 and 105 minutes after ingestion
increases
Not recorded as a finding: this platform holds no node for the endpoint
There was a greater increase in alpha activity across time in the L-theanine condition (relative to placebo (p+0.05).
PMID 18296328 · one of two readings recorded this
cigarette consumption and proportion of volunteer smokers who stopped smoking after 2 months of tea-filter use
decreases, cigarette consumption decreased by 56.5%; 31.7% stopped smoking
Not recorded as a finding: the intervention held more than the compound
In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking.
PMID 20596936 · one of two readings recorded this
cigarette consumption and smoking cessation after using tea filters on cigarettes for 2 months
decreases, cigarette consumption decreased by 56.5%; 31.7% stopped smoking
Not recorded as a finding: the intervention held more than the compound
In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking.
PMID 20596936 · one of two readings recorded this
cigarette consumption
decreases
In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking
PMID 20596936 · one of two readings recorded this
smoking cessation (proportion who stopped smoking)
increases
In one trial it was found that after using the tea filters for 2 months, the volunteer smokers decreased their cigarette consumption by 56.5%, and 31.7% of them stopped smoking
PMID 20596936 · one of two readings recorded this
anxiety, Hamilton Anxiety Rating Scale (HARS)
decreases, p = 0.015
Not recorded as a finding: node hamilton-anxiety-rating-scale-total-score requires the total score; the abstract says only 'anxiety ... measured by the HARS scale' and never states the total
Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).
PMID 21208586 · one of two readings recorded this
anxiety
decreases, p = 0.015
L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores
PMID 21208586 · one of two readings recorded this
CANTAB neurocognitive task scores
no effect
PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation
PMID 21208586 · one of two readings recorded this
general functioning, side effect and quality of life measures
no effect
PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation
PMID 21208586 · one of two readings recorded this
general psychopathology score
decreases, p = 0.001
L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores
PMID 21208586 · one of two readings recorded this
PANSS activation factor score (5-dimension model)
decreases, p = 0.006
L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo
PMID 21208586 · one of two readings recorded this
PANSS negative score, 3-dimension and unspecified model, clinician-rated
no effect, not affected by L-theanine augmentation
Not recorded as a finding: Node panss-negative-subscale-score exists, but the sentence pools it with CANTAB, functioning, side effects and quality of life in one agentless-style negation and does not state the model; put down to avoid a one-sided, multi-endpoint quote
PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation.
PMID 21208586 · one of two readings recorded this
PANSS negative score
no effect
Not recorded as a finding: stated as not affected, but the sentence also lumps CANTAB, functioning, side effects and quality of life and gives no estimate; no clean span for the PANSS negative node
PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation.
PMID 21208586 · one of two readings recorded this
PANSS negative score
no effect
PANSS negative and CANTAB task scores, general functioning, side effect, and quality of life measures were not affected by L-theanine augmentation
PMID 21208586 · one of two readings recorded this
PANSS positive and activation factor scores, 5-dimension model
decreases, positive P = .004, activation P = .006
Not recorded as a finding: 5-dimension factor scores are not the PANSS positive subscale defined by the node (7 items, 3-dimension model); near miss on instrument scoring
According to the 5-dimension model of psychopathology, L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo.
PMID 21208586 · one of two readings recorded this
PANSS positive score (5-dimension model)
decreases, p = 0.004
L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo
PMID 21208586 · one of two readings recorded this
positive score (3-dimensional model)
decreases, p = 0.009
L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores
PMID 21208586 · one of two readings recorded this
positive symptoms, PANSS positive factor (5-dimension model)
decreases, significant reductions in PANSS positive and activation factor scores compared with placebo, p = 0.004
Not recorded as a finding: no outcome node for PANSS positive or activation factor scores
According to the 5-dimension model of psychopathology, L-theanine produced significant reductions on PANSS positive (P = .004) and activation factor (P = .006) scores compared to placebo.
PMID 21208586 · one of two readings recorded this
psychopathology, PANSS positive and general psychopathology scores (3-dimensional model)
decreases, positive P = .009; general psychopathology P < .001, p = 0.009
Not recorded as a finding: no node for PANSS scores
Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).
PMID 21208586 · one of two readings recorded this
brain theta waves (temporal, frontal, parietal, occipital; eye-open and reading states)
increases
Brain theta waves, an indicator of cognitive alertness, were increased significantly in the temporal, frontal, parietal, and occipital areas after 3 hours in the eye-open and reading states
PMID 21303262 · one of two readings recorded this
delayed recognition
increases, p = 0.0572
LGNC-07 led to improvements in memory by marginally increasing delayed recognition in the Rey-Kim memory test (P = .0572)
PMID 21303262 · one of two readings recorded this
Rey-Kim memory quotient
increases
Stratified analyses showed that LGNC-07 improved memory and selective attention by significantly increasing the Rey-Kim memory quotient and word reading in the subjects with MMSE-K scores of 21-23 (LGNC-07, n = 11; placebo, n = 9)
PMID 21303262 · one of two readings recorded this
word reading (selective attention)
increases
Stratified analyses showed that LGNC-07 improved memory and selective attention by significantly increasing the Rey-Kim memory quotient and word reading in the subjects with MMSE-K scores of 21-23 (LGNC-07, n = 11; placebo, n = 9)
PMID 21303262 · one of two readings recorded this
Adherence to test capsules
Adherence to the test capsules was 93.2% in the catechin/theanine group and 91.9% in the placebo group
PMID 21338496 · one of two readings recorded this
Clinically defined influenza infection, all participants
clinically defined influenza infection occurred in a total of 17 participants (8.7%), 6 of whom (3.1%) were laboratory confirmed with the type A antigen
PMID 21338496 · one of two readings recorded this
incidence of clinically defined influenza infection (fever 37.8 C or above plus two of cough, sore throat, headache, myalgia), adjusted odds ratio
decreases, 4.1% versus 13.1%, adjusted OR 0.25 (95% CI 0.07 to 0.76), p = 0.022
Not recorded as a finding: the intervention held more than the compound
The incidence of clinically defined influenza infections was significantly lower in the catechin/theanine group (4 participants; 4.1%) than in the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022).
PMID 21338496 · one of two readings recorded this
incidence of clinically defined influenza infection (physician diagnosis on fever of 37.8 C or more plus two of cough, sore throat, headache, myalgia), primary outcome; also laboratory-confirmed influenza by antigen assay and time free from influenza
decreases, adjusted OR, 0.25; 95% CI, 0.07 to 0.76, p = 0.022
Not recorded as a finding: the intervention held more than the compound
The incidence of clinically defined influenza infections was significantly lower in the catechin/theanine group (4 participants; 4.1%) than in the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022).
PMID 21338496 · one of two readings recorded this
Incidence of clinically defined influenza infection
decreases, p = 0.022, n = 197
The incidence of clinically defined influenza infections was significantly lower in the catechin/theanine group (4 participants; 4.1%) than in the placebo group (13 participants; 13.1%) (adjusted OR, 0.25; 95% CI, 0.07 to 0.76, P = 0.022)
PMID 21338496 · one of two readings recorded this
Incidence of laboratory-confirmed influenza infection
no effect, p = 0.112, n = 197
The incidence of laboratory-confirmed influenza infection was also lower in the catechin/theanine group (1 participant; 1.0%) than in the placebo group (5 participants; 5.1%), but this difference was not significant (adjusted OR, 0.17; 95% CI, 0.01 to 1.10; P = 0.112)
PMID 21338496 · one of two readings recorded this
Time free from clinically defined influenza infection
decreases, p = 0.023, n = 197
The time for which the patient was free from clinically defined influenza infection, estimated with the Cox proportional hazards regression model, was significantly different between the two groups (adjusted hazard ratio, 0.27; 95% CI, 0.09 to 0.84; P = 0.023)
PMID 21338496 · one of two readings recorded this
activation factor and dysphoric mood vs change in cortisol-to-DHEAS*100 molar ratio (share of variance)
unclear
the changes in cortisol-to-DHEAS*100 molar ratio accounted for 30% to 34% of the variance in activation factor and dysphoric mood scores and for 15.9% in anxiety scores
PMID 21617527 · one of two readings recorded this
anxiety score vs change in cortisol-to-DHEAS*100 molar ratio (share of variance)
unclear
the changes in cortisol-to-DHEAS*100 molar ratio accounted for 30% to 34% of the variance in activation factor and dysphoric mood scores and for 15.9% in anxiety scores
PMID 21617527 · one of two readings recorded this
reduction of anxiety score vs change in serum BDNF (share of variance)
unclear
Variability of serum BDNF levels accounted for 26.2% of the total variance in reduction of dysphoric mood and 38.2% in anxiety scores
PMID 21617527 · one of two readings recorded this
reduction of dysphoric mood vs change in serum BDNF (share of variance)
unclear
Variability of serum BDNF levels accounted for 26.2% of the total variance in reduction of dysphoric mood and 38.2% in anxiety scores
PMID 21617527 · one of two readings recorded this
regression of symptom improvement on neurochemical changes
no effect
Regression models among placebo-treated patients did not reach significant level
PMID 21617527 · one of two readings recorded this
activity during sleep (time awake after sleep onset)
no effect
along with a non-significant trend for less activity during sleep (defined as less time awake after sleep onset) compared to those in the placebo group
PMID 22214254 · one of two readings recorded this
Pediatric Sleep Questionnaire correlation with actigraphy
no effect
The PSQ data did not correlate significantly to the objective data gathered from actigraphy
PMID 22214254 · one of two readings recorded this
sleep efficiency
increases
boys who consumed L-theanine obtained significantly higher sleep percentage and sleep efficiency scores
PMID 22214254 · one of two readings recorded this
sleep latency and other sleep parameters
no effect
Sleep latency and other sleep parameters were unchanged
PMID 22214254 · one of two readings recorded this
sleep percentage
increases
boys who consumed L-theanine obtained significantly higher sleep percentage and sleep efficiency scores
PMID 22214254 · one of two readings recorded this
L-theanine in plasma, erythrocytes and urine, capsules versus green tea
no effect, n = 12
L-Theanine increased in plasma, erythrocytes, and urine with comparable results after both treatments
PMID 23096008 · one of two readings recorded this
plasma and urinary ethylamine and glutamic acid
increases
ethylamine and glutamic acid increased in plasma and were excreted by urine after intake of capsules and tea
PMID 23096008 · one of two readings recorded this
plasma L-theanine AUC
increases, n = 3
The AUC of L-theanine in plasma increased dose dependently after intake of 50, 100, and 200 mg L-theanine via capsules
PMID 23096008 · one of two readings recorded this
morning pre-practice salivary alpha-amylase activity (sAA)
decreases, p = 0.032
In the placebo-group, sAA in the morning (pre-practice sAA) was higher than in theanine-group during the pharmacy practice (p=0.032)
PMID 24051231 · one of two readings recorded this
salivary alpha-amylase activity (sAA), morning, as a marker of sympathetic nervous system activity; subjective stress
decreases, morning sAA higher in the placebo group than in the theanine group, p = 0.032
Not recorded as a finding: this platform holds no node for the endpoint
In the placebo-group, sAA in the morning (pre-practice sAA) was higher than in theanine-group during the pharmacy practice (p=0.032).
PMID 24051231 · one of two readings recorded this
sleeping time versus pre-practice sAA
decreases
higher pre-practice sAA was correlated to shorter sleeping time in both groups (p=0.41×10(-3))
PMID 24051231 · one of two readings recorded this
subjective stress (instrument not named in the abstract); salivary alpha-amylase activity as a marker of sympathetic activity
decreases, p = 0.02
Not recorded as a finding: the paper never states the instrument the node requires
Subjective stress was significantly lower in the theanine-group than in the placebo-group (p=0.020).
PMID 24051231 · one of two readings recorded this
subjective stress
decreases, p = 0.02
Subjective stress was significantly lower in the theanine-group than in the placebo-group (p=0.020)
PMID 24051231 · one of two readings recorded this
trait anxiety versus pre-practice sAA
increases, p = 0.015
students with higher pre-practice sAA showed significantly higher trait anxiety in both groups (p=0.015)
PMID 24051231 · one of two readings recorded this
habituation of startle response
no effect
There was no significant relation between the dose of l-theanine and the startle magnitude or the habituation of startle response
PMID 24372613 · one of two readings recorded this
plasma l-theanine concentration
increases
The plasma concentrations of l-theanine correlated with the dose of l-theanine
PMID 24372613 · one of two readings recorded this
% PPI (prepulse inhibition)
increases
The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg)
PMID 24372613 · one of two readings recorded this
% PPI (prepulse inhibition)
increases
The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg)
PMID 24372613 · one of two readings recorded this
% PPI (prepulse inhibition)
no effect
The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg)
PMID 24372613 · one of two readings recorded this
sensorimotor gating, percent prepulse inhibition (% PPI) of the startle response
increases, 200 mg and 400 mg, but not 600 mg, increased % PPI compared with 0 mg
Not recorded as a finding: this platform holds no node for the endpoint
The administration of 200 mg of l-theanine and that of 400 mg, but not 600 mg, significantly increased the % PPI compared to the baseline (0 mg).
PMID 24372613 · one of two readings recorded this
startle magnitude
no effect
There was no significant relation between the dose of l-theanine and the startle magnitude or the habituation of startle response
PMID 24372613 · one of two readings recorded this
anxiety, Hamilton Scale for Anxiety (HAM-A); negative symptoms, SANS
decreases
Not recorded as a finding: the intervention held more than the compound
Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A), and elevation of general functioning (GAF).
PMID 26218236 · one of two readings recorded this
anxiety scores (anxious mood, tension, cardiovascular symptoms)
decreases
Add-on PREG-LT also significantly associated with a reduction of anxiety scores such as anxious mood, tension, and cardiovascular symptoms (HAM-A)
PMID 26218236 · one of two readings recorded this
general functioning
increases
elevation of general functioning (GAF)
PMID 26218236 · one of two readings recorded this
negative symptoms (blunted affect, alogia, anhedonia)
decreases
Negative symptoms such as blunted affect, alogia, and anhedonia (SANS) were found to be significantly improved with moderate effect sizes among patients who received PREG-LT, in comparison with the placebo group
PMID 26218236 · one of two readings recorded this
Alertness response to multi-tasking framework (baseline-adjusted)
no effect, p = 0.375, n = 26
Alertness | 26 | −0.72 | 3.86 | 5.28 | 5.69 | 0.375 | 0.267
PMID 26797633 · one of two readings recorded this
Baseline-adjusted ΔΔ stress to multi-tasking framework
n = 26
Active | 26 | −13.73 | (18.49) | −6.38 | (23.48)
PMID 26797633 · one of two readings recorded this
Baseline-adjusted ΔΔ stress to multi-tasking framework
n = 26
Active | 26 | −13.73 | (18.49) | −6.38 | (23.48)
PMID 26797633 · one of two readings recorded this
Baseline-adjusted ΔΔ stress to multi-tasking framework
n = 26
Placebo | 26 | 1.58 | (21.54) | −6.08 | (21.70)
PMID 26797633 · one of two readings recorded this
Baseline-adjusted ΔΔ stress to multi-tasking framework
n = 26
Placebo | 26 | 1.58 | (21.54) | −6.08 | (21.70)
PMID 26797633 · one of two readings recorded this
Calmness response to multi-tasking framework (baseline-adjusted)
no effect, p = 0.624, n = 26
Calmness | 26 | −0.31 | 3.87 | 0.25 | 0.04 | 0.624 | 0.418
PMID 26797633 · one of two readings recorded this
Change in posterior resting alpha versus trait anxiety score
increases, p = 0.026, n = 17
the change in posterior resting alpha was significantly correlated with trait anxiety scores (rs = 0.477, p = 0.026, one-tailed; see Figure 5)
PMID 26797633 · one of two readings recorded this
Cognitive performance on MTF (overall score change from baseline)
no effect, p = 0.05, n = 25
Two-way repeated measures ANOVA showed no significant main effect of treatment (F(1,24) = 1.12, p > 0.05)
PMID 26797633 · one of two readings recorded this
Cognitive performance on MTF (overall score change from baseline)
increases, p = 0.016, n = 25
however, a significant main effect of assessment time point (F(1,24) = 6.66, p = 0.016)
PMID 26797633 · one of two readings recorded this
Contentedness response to multi-tasking framework (baseline-adjusted)
no effect, p = 0.885, n = 26
Contentedness | 26 | −0.56 | 1.41 | 1.99 | 0.62 | 0.885 | 0.152
PMID 26797633 · one of two readings recorded this
Fatigue response to multi-tasking framework (baseline-adjusted)
no effect, p = 0.663, n = 25
Fatigue | 25 | −3.32 | −5.96 | −4.80 | −7.44 | 0.663 | 0.999
PMID 26797633 · one of two readings recorded this
Posterior resting alpha activity, active vs placebo
increases, p = 0.019, n = 9
posterior resting alpha was significantly higher at the active treatment visit contrasted with placebo for the high trait anxiety group (t(8) = 2.51, p = 0.019, one-tailed)
PMID 26797633 · one of two readings recorded this
Posterior resting alpha activity, active vs placebo
no effect, p = 0.1, n = 8
while there was no significant change in the low anxiety group (t(7) = −0.12, p > 0.1)
PMID 26797633 · one of two readings recorded this
Posterior resting relative alpha power (MEG)
unclear, p = 0.055, n = 17
Testing mean relative alpha in posterior regions between placebo and active visits showed a non-significant trend towards greater posterior alpha activity after active treatment (t(16) = 1.68, p = 0.055, one-tailed)
PMID 26797633 · one of two readings recorded this
Pre-stressor tranquil-troubled rating at rest (change from baseline)
n = 26
Active | 26 | 0.69 | (9.69) | 1.50 | (15.19)
PMID 26797633 · one of two readings recorded this
Pre-stressor tranquil-troubled rating at rest (change from baseline)
n = 26
Active | 26 | 0.69 | (9.69) | 1.50 | (15.19)
PMID 26797633 · one of two readings recorded this
Pre-stressor tranquil-troubled rating at rest (change from baseline)
n = 26
Placebo | 26 | 4.23 | (13.61) | 2.54 | (11.83)
PMID 26797633 · one of two readings recorded this
Pre-stressor tranquil-troubled rating at rest (change from baseline)
n = 26
Placebo | 26 | 4.23 | (13.61) | 2.54 | (11.83)
PMID 26797633 · one of two readings recorded this
Resting state posterior alpha activity
n = 9
Active | 42.95 | (14.28) | 45.19 | (10.63)
PMID 26797633 · one of two readings recorded this
Resting state posterior alpha activity
n = 8
Active | 42.95 | (14.28) | 45.19 | (10.63)
PMID 26797633 · one of two readings recorded this
Resting state posterior alpha activity
n = 9
Placebo | 43.12 | (11.94) | 41.46 | (11.56)
PMID 26797633 · one of two readings recorded this
Resting state posterior alpha activity
n = 8
Placebo | 43.12 | (11.94) | 41.46 | (11.56)
PMID 26797633 · one of two readings recorded this
Salivary cortisol response to multi-tasking framework (change pre- to post-stressor)
no effect, p = 0.05
Results of Wilcoxon signed ranks tests showed no significant differences in cortisol change between active treatment compared to placebo 1 h post-dose (z = 1.28, p > 0.05, median cortisol response: placebo = −0.19, active = −0.02)
PMID 26797633 · one of two readings recorded this
Salivary cortisol response to multi-tasking framework (change pre- to post-stressor)
decreases, p = 0.047
but a significantly lower cortisol response 3 h post-dose for the active treatment visit (z = −1.98, p = 0.047, median cortisol response: placebo = 0.44, active = −0.09)
PMID 26797633 · one of two readings recorded this
State anxiety response to multi-tasking framework (baseline-adjusted)
no effect, p = 0.201, n = 26
Anxiety (STAI-S) | 26 | 1.50 | −1.81 | 0.12 | −1.00 | 0.201 | 0.251
PMID 26797633 · one of two readings recorded this
subjective stress response to a 20-minute multi-tasking cognitive stressor, 100-mm stress visual analogue scale, baseline-adjusted change; also salivary cortisol (ELISA), fatigue and STAI-S anxiety
decreases, p = 0.003, n = 26
Not recorded as a finding: the intervention held more than the compound
Paired comparisons showed significantly reduced subjective stress response 1 h post-dose for the active treatment when compared to placebo treatment (p = 0.003), but no significant difference between treatments in stress response at 3 h post-dose (p > 0.05).
PMID 26797633 · one of two readings recorded this
subjective stress response to a multitasking cognitive stressor, 100-mm stress visual analogue scale, baseline-adjusted change
decreases, stress response reduced 1 h post-dose for active versus placebo; no significant difference at 3 h, p = 0.003
Not recorded as a finding: the intervention held more than the compound
Paired comparisons showed significantly reduced subjective stress response 1 h post-dose for the active treatment when compared to placebo treatment (p = 0.003), but no significant difference between treatments in stress response at 3 h post-dose (p > 0.05).
PMID 26797633 · one of two readings recorded this
Subjective stress response to multi-tasking framework (baseline-adjusted ΔΔ stress, VAS)
decreases, p = 0.003, n = 26
Paired comparisons showed significantly reduced subjective stress response 1 h post-dose for the active treatment when compared to placebo treatment (p = 0.003)
PMID 26797633 · one of two readings recorded this
Subjective stress response to multi-tasking framework (baseline-adjusted ΔΔ stress, VAS)
no effect, p = 0.05, n = 26
but no significant difference between treatments in stress response at 3 h post-dose (p > 0.05)
PMID 26797633 · one of two readings recorded this
Subjective stress response to multi-tasking framework (baseline-adjusted ΔΔ stress, VAS)
decreases, p = 0.017, n = 26
a significant assessment time by treatment interaction was observed (F(1,25) = 6.50, p = 0.017, partial η2 = 0.206)
PMID 26797633 · one of two readings recorded this
Subjective stress response to multi-tasking framework (change without baseline adjustment)
decreases, p = 0.006, n = 26
showed significantly reduced stress response 1 h post-dose for the active treatment when compared to the placebo treatment (T(25) = 3.03, p = 0.006)
PMID 26797633 · one of two readings recorded this
Mini-Mental State Examination (MMSE)
increases
MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm
PMID 29188854 · one of two readings recorded this
Mini-Mental State Examination score; Perceived Stress Questionnaire index; Self-Rating Depression Scale
increases, MMSE and PSQ Index significantly improved in the active arm versus baseline and versus the parallel arm, n = 30
Not recorded as a finding: the intervention held more than the compound
MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm.
PMID 29188854 · one of two readings recorded this
Mini-Mental State Examination total score; Perceived Stress Questionnaire Index; Self-Rating Depression Scale
increases, n = 30
Not recorded as a finding: the intervention held more than the compound
MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm.
PMID 29188854 · one of two readings recorded this
Perceived Stress Questionnaire (PSQ) Index
unclear
MMSE and PSQ Index significantly improved in the active treatment arm, both versus baseline and versus the parallel arm
PMID 29188854 · one of two readings recorded this
Self-Rating Depression Scale (SRDS) score
unclear
Both groups experienced a significant improving in the SRDS scores
PMID 29188854 · one of two readings recorded this
Blinding: correct guess of treatment allocation
n = 95
just over half of all participants (60%) guessed the nature of their treatment correctly (with 49% accuracy in the nutrient enriched condition alone)
PMID 29215606 · one of two readings recorded this
Bond-Lader alertness, main effect of treatment
increases, p = 0.004, n = 95
there was a significant main effect of treatment on Bond-Lader ratings of “alertness” (F(1, 93) = 8.919, p = 0.004)
PMID 29215606 · one of two readings recorded this
Cognitive Demand Battery RVIP accuracy
increases, p = 0.001, n = 95
with the nutrient enriched intervention leading to improvements in accuracy across Day 1 and Day 56 (F(1, 75) = 47.7, p < 0.001)
PMID 29215606 · one of two readings recorded this
Cognitive Demand Battery RVIP speed
increases, p = 0.006, n = 95
improved speed of performance (main treatment effect (F(1, 75) = 8.1, p = 0.006))
PMID 29215606 · one of two readings recorded this
Cognitive Demand Battery Serial 3s correct subtractions
increases, p = 0.001, n = 95
Serial 3s (F(1, 93) = 24.4, p < 0.001); Serial 7s (F(1, 93) = 13.4, p < 0.001)
PMID 29215606 · one of two readings recorded this
Cognitive Demand Battery Serial 7s correct subtractions
increases, p = 0.001, n = 95
Serial 3s (F(1, 93) = 24.4, p < 0.001); Serial 7s (F(1, 93) = 13.4, p < 0.001)
PMID 29215606 · one of two readings recorded this
COMPASS cognitive tasks (RVIP accuracy and speed, Corsi blocks span, serial subtractions, word recall), Bond-Lader alertness, mental fatigue VAS
increases, Corsi blocks span score, main effect of treatment across post-dose assessments, p = 0.004
Not recorded as a finding: the intervention held more than the compound
With regard to working memory, there was a significant main effect on the Corsi blocks span score (F(1, 93) = 8.49, p = 0.004), with the nutrient enriched treatment being associated with improved working memory capacity across post-dose assessments on Day 1 and Day 56.
PMID 29215606 · one of two readings recorded this
Corsi blocks span score, main effect of treatment
increases, p = 0.004, n = 95
there was a significant main effect on the Corsi blocks span score (F(1, 93) = 8.49, p = 0.004)
PMID 29215606 · one of two readings recorded this
Delayed Word Recall errors, main effect of treatment
decreases, p = 0.029, n = 95
main effects seen in terms of a reduced number of errors committed on the Delayed Word Recall task (F(1, 92) = 4.94, p = 0.029)
PMID 29215606 · one of two readings recorded this
Numeric Working Memory accuracy, assessment x treatment interaction
no effect, p = 0.04, n = 95
There was also a significant assessment × treatment interaction (F(1, 93) = 4.345, p = 0.04) with regards the accuracy of performing the Numeric Working Memory task
PMID 29215606 · one of two readings recorded this
Peg and Ball errors, post-hoc comparison
decreases, p = 0.05, n = 95
increased accuracy of performance following the nutrient enriched bar which was restricted to the 40 min post-dose assessment (t (93) = 2.55, p < 0.05)
PMID 29215606 · one of two readings recorded this
Peg and Ball errors, treatment x assessment interaction
modulates, p = 0.036, n = 95
there was also significant treatment × assessment interaction (F(1, 93) = 4.55, p = 0.036) with regards the number of errors committed during the same task
PMID 29215606 · one of two readings recorded this
Peg and Ball thinking time, post-hoc comparison
decreases, p = 0.01, n = 95
participants required a shorter amount of time to plan their moves following consumption of the nutrient enriched intervention but only on Day 56 (t (93) = 3.57, p < 0.01)
PMID 29215606 · one of two readings recorded this
Peg and Ball thinking time, treatment x day interaction
modulates, p = 0.014, n = 95
there was a significant treatment × day interaction (F(1, 93) = 6.33, p = 0.014) on the Peg and Ball task in terms of “thinking time”
PMID 29215606 · one of two readings recorded this
Picture Recognition accuracy, post-hoc comparison
decreases, p = 0.05, n = 95
this effect represented a decrement in performance on Day 1 (t (93) = 2.44, p < 0.05), with a trend towards improved performance on Day 56 (t (93) = 1.99, p < 0.1)
PMID 29215606 · one of two readings recorded this
Picture Recognition accuracy, post-hoc comparison
unclear, p = 0.1, n = 95
this effect represented a decrement in performance on Day 1 (t (93) = 2.44, p < 0.05), with a trend towards improved performance on Day 56 (t (93) = 1.99, p < 0.1)
PMID 29215606 · one of two readings recorded this
Picture Recognition accuracy, treatment x day interaction
modulates, p = 0.015, n = 95
there was also a significant treatment × day interaction (F(1, 90) = 6.15, p = 0.015) in terms of accuracy of performance
PMID 29215606 · one of two readings recorded this
Picture Recognition speed, main effect of treatment
increases, p = 0.002, n = 95
improved speed of performing the Picture Recognition task (F(1, 90) = 9.9, p = 0.002) across post-dose assessments on Day 1 and Day 56
PMID 29215606 · one of two readings recorded this
Pure chronic effect on pre-dose performance, any task
no effect, n = 95
There were no significant differences in performance for any task during the pre-dose assessment on Day 56 that would indicate a chronic effect of treatment in the absence of any acute effects
PMID 29215606 · one of two readings recorded this
RVIP accuracy, assessment x treatment interaction
modulates, p = 0.014, n = 95
There was also a significant assessment x treatment interaction (F(1, 87) = 6.29, p = 0.014) with regards the same measure
PMID 29215606 · one of two readings recorded this
RVIP accuracy, main effect of treatment
increases, p = 0.001, n = 95
there was a significant main effect of treatment with regards the accuracy of performing the Rapid Visual Information Processing (RVIP) task (F(1, 87) = 24.74, p < 0.001)
PMID 29215606 · one of two readings recorded this
RVIP accuracy, post-hoc comparison
increases, p = 0.001, n = 95
accuracy was improved during both assessments (40 min (t (87) = 4.65, p < 0.001), 160 min (t (93) = 7.59, p < 0.001))
PMID 29215606 · one of two readings recorded this
RVIP accuracy, post-hoc comparison
increases, p = 0.001, n = 95
accuracy was improved during both assessments (40 min (t (87) = 4.65, p < 0.001), 160 min (t (93) = 7.59, p < 0.001))
PMID 29215606 · one of two readings recorded this
RVIP speed, main effect of treatment
increases, p = 0.002, n = 95
With regards the speed of performing the RVIP task, there was also a significant main effect of treatment (F(1, 87) = 10.29, p = 0.002)
PMID 29215606 · one of two readings recorded this
Subjective mental fatigue during Cognitive Demand Battery
decreases, p = 0.001, n = 95
subjective ratings of mental fatigue (measured after each repetition of the three CDB tasks) was also significantly reduced across Days 1 and 56 following the nutrient enriched intervention (F(3, 279) = 22.5, p < 0.001)
PMID 29215606 · one of two readings recorded this
cognitive impairment
unclear
the current literature supports the use of Ginkgo biloba, resveratrol, epigallocatechin-3-gallate and l-theanine, Theobroma cacao, Bacopa monnieri, Crocus sativus and curcumin
PMID 29289576 · one of two readings recorded this
urinary 3-methyl-2-oxovalerate level
increases
The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate
PMID 30574780 · one of two readings recorded this
urinary epicatechin excretion
increases
The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate
PMID 30574780 · one of two readings recorded this
urinary excretion of theanine and other metabolites by untargeted 1H NMR metabolomics after a high-catechin tea
increases, consumption of the high-catechin tea resulted in excretion of theanine
Not recorded as a finding: the compound is what was measured, not what was given
The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate, as well as unknown compounds.
PMID 30574780 · one of two readings recorded this
urinary pyrogallol sulfate excretion
increases
The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate
PMID 30574780 · one of two readings recorded this
urinary succinate level
increases
The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate
PMID 30574780 · one of two readings recorded this
urinary theanine excretion
increases
The consumption of the HCT resulted in the excretion of theanine, epicatechin, pyrogallol sulfate, and higher levels of 3-methyl-2-oxovalerate and succinate
PMID 30574780 · one of two readings recorded this
anxiety reduction on the HAMA
no effect, p = 0.73
adjunctive L-theanine did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35)
PMID 30580081 · one of two readings recorded this
insomnia severity on the Insomnia Severity Index
no effect, p = 0.35
adjunctive L-theanine did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35)
PMID 30580081 · one of two readings recorded this
insomnia severity on the Insomnia Severity Index
unclear, p = 0.007
a separation in favour of L-theanine was noted on the ISI in those with non-clinical levels of insomnia symptoms (ISI ≤ 14; p = 0.007)
PMID 30580081 · one of two readings recorded this
modified emotional Stroop
no effect
No significant cognitive effects (trail making time and the modified emotional Stroop) were revealed
PMID 30580081 · one of two readings recorded this
self-reported sleep satisfaction (ISI item 4)
increases, p = 0.015
LT treated participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015)
PMID 30580081 · one of two readings recorded this
sleep satisfaction, Insomnia Severity Index item 4
increases, greater self-reported sleep satisfaction than placebo, p = 0.015
Not recorded as a finding: single ISI item, not the total score the insomnia node requires; no node for an item score
However, LT treated participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015).
PMID 30580081 · one of two readings recorded this
sleep satisfaction, ISI item 4 (single item)
increases, greater self-reported sleep satisfaction than placebo, p = 0.015
Not recorded as a finding: no node for a single ISI item; node requires the 7-item total
However, LT treated participants reported greater self-reported sleep satisfaction than placebo (ISI item 4; p = 0.015).
PMID 30580081 · one of two readings recorded this
trail making time
no effect
No significant cognitive effects (trail making time and the modified emotional Stroop) were revealed
PMID 30580081 · one of two readings recorded this
2000-m ergometer mean power output
no effect, n = 20
Power (Watt) | 436 ± 28.5 | 445 ± 17.52 | 401 ± 31.48 | 411 ± 36.69
PMID 30770758 · one of two readings recorded this
2000-m ergometer relative power output
no effect, n = 20
(W x kg−1) | 5.01 ± 0.37 | 5.02 ± 0.28 | 4.81 ± 0.44 | 4.93 ± 0.22
PMID 30770758 · one of two readings recorded this
2000-m ergometer time
no effect, n = 20
Time (s) | 371.3 ± 8.47 | 368.7 ± 5.22 | 382.1 ± 12.98 | 379.2 ± 11.78
PMID 30770758 · one of two readings recorded this
2000-m rowing ergometer time trial, total run time (and mean power output), before versus after 6 weeks of 150 mg L-theanine extract or placebo; the only sentence reports intragroup differences and no between-arm sentence gives the time
no effect
Not recorded as a finding: the result compares a group with itself, not with a control
No significant intragroup differences were found in mean power output and total run time during the 2000-m test performed at the beginning and at the end of the training camp (1st and 2nd examination, respectively).
PMID 30770758 · one of two readings recorded this
Blood lactate maximum (LAmax) around the 2000-m test
no effect, n = 20
LAmax (mmol x L−1)a | 15.1 ± 2.31 | 11.6 ± 2.42 | 14.1 ± 3.18 | 12.3 ± 4.13
PMID 30770758 · one of two readings recorded this
Blood lactate minimum (LAmin) around the 2000-m test
no effect, n = 20
LAmin (mmol x L−1)a | 1.6 ± 0.37 | 1.5 ± 0.81 | 1.8 ± 0.73 | 1.6 ± 0.25
PMID 30770758 · one of two readings recorded this
CTL count
no effect, p = 0.294, n = 20
Nevertheless, the main effect of the supplementation on CTL count did not turn out to be statistically significant on ANOVA (p = 0.294)
PMID 30770758 · one of two readings recorded this
Granulocyte percentage
no effect, p = 0.8803, n = 20
Granulocytes [%] | LTE | 46.0 ± 10.81 | 47.6 ± 3.85 | 52.6 ± 5.53 | 46.4 ± 3.69 | 41.9 ± 5.37 | 51.3 ± 6.25† | < 0.0001 | 0.8803 | 0.4637
PMID 30770758 · one of two readings recorded this
Granulocyte percentage
no effect, n = 20
Pla | 48.9 ± 5.68 | 47.8 ± 6.22 | 48.8 ± 5.44 | 45.5 ± 3.58 | 43.4 ± 7.35 | 49.9 ± 6.04
PMID 30770758 · one of two readings recorded this
Lymphocyte percentage
no effect, p = 0.5098, n = 20
Lymphocytes [%] | LTE | 42.73 ± 7.85 | 44.59 ± 4.21 | 38.44 ± 6.04 | 43.48 ± 3.08 | 48.36 ± 4.93 | 38.79 ± 5.35† | < 0.0001 | 0.5098 | 0.5920
PMID 30770758 · one of two readings recorded this
Lymphocyte percentage
no effect, n = 20
Pla | 43.19 ± 5.32 | 45.13 ± 6.59 | 42.83 ± 6.02 | 44.98 ± 3.39 | 47.62 ± 6.99 | 40.17 ± 6.19†
PMID 30770758 · one of two readings recorded this
Serum IFN-γ concentration
no effect, p = 0.172, n = 20
Statistical analysis showed that supplementation with L-theanine did not exert a significant effect on IFN-γ levels (main effect, p = 0.172)
PMID 30770758 · one of two readings recorded this
Serum IL-10 concentration
no effect, p = 0.943, n = 20
Although supplementation with L-theanine did not exert a significant effect on IL-10 level (main effect, p = 0.943)
PMID 30770758 · one of two readings recorded this
Serum IL-2 concentration
no effect, p = 0.981, n = 20
this parameter turned out to be independent of L-theanine supplementation (ANOVA, main effect, p = 0.981)
PMID 30770758 · one of two readings recorded this
Serum IL-4 concentration
no effect, p = 0.508, n = 20
This parameter turned out to be modulated by neither physical exercise (main effect, p = 0.662) nor supplementation (main effect, p = 0.508)
PMID 30770758 · one of two readings recorded this
Tδγ cell count
no effect, p = 0.156, n = 20
The main effect of the supplementation on Tδγ cell count did not turn out to be statistically significant (p = 0.156)
PMID 30770758 · one of two readings recorded this
Total antioxidant capacity (TAC)
no effect, p = 0.2035, n = 20
TAC (mmol/l) | LTE | 2.36 ± 0.38 | 1.78 ± 0.40* | 2.11 ± 0.55 | 2.22 ± 0.44 | 1.80 ± 0.35 | 2.43 ± 0.41† | < 0.0001 | 0.2035 | 0.5617
PMID 30770758 · one of two readings recorded this
Total antioxidant capacity (TAC)
no effect, n = 20
Pla | 2.49 ± 0.22 | 1.65 ± 0.28* | 2.18 ± 0.42 | 1.87 ± 0.46 | 1.69 ± 0.24 | 2.39 ± 0.46
PMID 30770758 · one of two readings recorded this
Treg count
no effect, p = 0.149, n = 20
ANOVA demonstrated that supplementation with L-theanine did not exert a statistically significant effect on Treg count (main effect, p = 0.149)
PMID 30770758 · one of two readings recorded this
Treg to CTL ratio
no effect, p = 0.771, n = 20
Statistical analysis showed that the values of Treg to CTL ratio were modulated by the exercise, but not by the supplementation (p < 0.001 and p = 0.771, respectively; Fig. 4d)
PMID 30770758 · one of two readings recorded this
Treg to NK ratio
no effect, p = 0.233, n = 20
Statistical analysis showed that the values of Treg to NK ratio were influenced by physical exercise (p < 0.001), but not by the supplementation (p = 0.233)
PMID 30770758 · one of two readings recorded this
Treg to (NK + Tδγ + CTL) ratio
no effect, p = 0.053, n = 20
ANOVA showed that the main effect of the supplementation on Treg to (NK+ Tδγ + CTL) ratio was not statistically significant (p = 0.053)
PMID 30770758 · one of two readings recorded this
Treg to Tδγ ratio
no effect, p = 0.156, n = 20
but not by the LTE supplementation (main effect, p = 0.156)
PMID 30770758 · one of two readings recorded this
White blood cell count
no effect, p = 0.2236, n = 20
WBC [109/L] | LTE | 6.81 ± 1.47 | 11.16 ± 1.52* | 6.53 ± 1.04† | 6.25 ± 1.17 | 11.12 ± 1.96* | 6.46 ± 1.51† | < 0.0001 | 0.2236 | 0.7378
PMID 30770758 · one of two readings recorded this
White blood cell count
no effect, n = 20
Pla | 5.98 ± 1.27 | 10.1 ± 1.56* | 5.75 ± 0.75† | 6.03 ± 1.13 | 10.83 ± 1.91* | 6.0 ± 0.74†
PMID 30770758 · one of two readings recorded this
BACS executive function
increases, p = 0.031
The BACS verbal fluency, especially letter fluency (p = 0.001), and executive function scores were significantly increased after L-theanine administration (p = 0.001 and 0.031, respectively
PMID 31623400 · one of two readings recorded this
BACS letter fluency
increases, p = 0.001
The BACS verbal fluency, especially letter fluency (p = 0.001), and executive function scores were significantly increased after L-theanine administration (p = 0.001 and 0.031, respectively
PMID 31623400 · one of two readings recorded this
BACS verbal fluency
increases, p = 0.001
The BACS verbal fluency, especially letter fluency (p = 0.001), and executive function scores were significantly increased after L-theanine administration (p = 0.001 and 0.031, respectively
PMID 31623400 · one of two readings recorded this
change in BACS executive function
increases, p = 0.048, n = 21
The results were essentially unchanged (n = 21; verbal fluency: p = 0.023, letter fluency: p = 0.040, and executive function: p = 0.048; Supplementary Table S1)
PMID 31623400 · one of two readings recorded this
change in BACS executive function
unclear, p = 0.062
the BACS executive function score improvement tended to be greater in the L-theanine period than in the placebo period among the lower half of the group (p = 0.062)
PMID 31623400 · one of two readings recorded this
change in BACS letter fluency
increases, p = 0.04, n = 21
The results were essentially unchanged (n = 21; verbal fluency: p = 0.023, letter fluency: p = 0.040, and executive function: p = 0.048; Supplementary Table S1)
PMID 31623400 · one of two readings recorded this
change in BACS letter fluency
increases, p = 0.002
improvement in the BACS verbal fluency (p = 0.002), especially letter fluency (p = 0.002), score was significantly greater during the L-theanine period than the placebo period
PMID 31623400 · one of two readings recorded this
change in BACS verbal fluency
increases, p = 0.023, n = 21
The results were essentially unchanged (n = 21; verbal fluency: p = 0.023, letter fluency: p = 0.040, and executive function: p = 0.048; Supplementary Table S1)
PMID 31623400 · one of two readings recorded this
change in BACS verbal fluency
increases, p = 0.002
improvement in the BACS verbal fluency (p = 0.002), especially letter fluency (p = 0.002), score was significantly greater during the L-theanine period than the placebo period
PMID 31623400 · one of two readings recorded this
change in cognitive function scores
no effect
When score changes were compared between the L-theanine and placebo administrations, no significant difference was found for any cognitive function
PMID 31623400 · one of two readings recorded this
change in PSQI sleep disturbance subscale
decreases, p = 0.046
changes in the PSQI sleep latency, sleep disturbance, and use of sleep medication subscales were significantly greater (p = 0.0499, 0.046, and 0.047, respectively)
PMID 31623400 · one of two readings recorded this
change in PSQI sleep latency subscale
decreases, p = 0.0499
changes in the PSQI sleep latency, sleep disturbance, and use of sleep medication subscales were significantly greater (p = 0.0499, 0.046, and 0.047, respectively)
PMID 31623400 · one of two readings recorded this
change in PSQI total score
unclear, p = 0.073
those in the SDS and PSQI scores showed a non-statistically significant trend towards greater improvement (p = 0.084 and 0.073, respectively)
PMID 31623400 · one of two readings recorded this
change in PSQI use of sleep medication subscale
decreases, p = 0.047
changes in the PSQI sleep latency, sleep disturbance, and use of sleep medication subscales were significantly greater (p = 0.0499, 0.046, and 0.047, respectively)
PMID 31623400 · one of two readings recorded this
change in SDS score
unclear, p = 0.084
those in the SDS and PSQI scores showed a non-statistically significant trend towards greater improvement (p = 0.084 and 0.073, respectively)
PMID 31623400 · one of two readings recorded this
other biochemical indices
no effect
No other significantly altered indices were found after either L-theanine or placebo administration
PMID 31623400 · one of two readings recorded this
PSQI daytime dysfunction subscale
decreases, p = 0.022
the scores of “sleep latency” and “daytime dysfunction” significantly improved in response to L-theanine administration (p = 0.036 and 0.022, respectively)
PMID 31623400 · one of two readings recorded this
PSQI sleep latency subscale
decreases, p = 0.036
the scores of “sleep latency” and “daytime dysfunction” significantly improved in response to L-theanine administration (p = 0.036 and 0.022, respectively)
PMID 31623400 · one of two readings recorded this
PSQI total score
decreases, p = 0.013
The SDS, STAI-trait (T), and PSQI scores were significantly improved after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively
PMID 31623400 · one of two readings recorded this
SDS score
decreases, p = 0.019
The SDS, STAI-trait (T), and PSQI scores were significantly improved after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively
PMID 31623400 · one of two readings recorded this
serum L-theanine concentration
increases, p = 0.028
There was a significant difference in the serum L-theanine concentration between the L-theanine and placebo administrations (p = 0.028)
PMID 31623400 · one of two readings recorded this
serum L-theanine concentration
increases, p = 0.002
The serum L-theanine concentration was significantly increased after L-theanine administration (p = 0.002)
PMID 31623400 · one of two readings recorded this
STAI-trait score
decreases, p = 0.006
The SDS, STAI-trait (T), and PSQI scores were significantly improved after L-theanine administration (p = 0.019, 0.006, and 0.013, respectively
PMID 31623400 · one of two readings recorded this
stress-related symptom scores (SDS, STAI-T, PSQI)
no effect
In contrast, there was no significant difference after placebo administration
PMID 31623400 · one of two readings recorded this
Trail Making Test A
decreases, p = 0.042
the Trail Making Test A and B scores were significantly improved after placebo administration (p = 0.042 and 0.038, respectively)
PMID 31623400 · one of two readings recorded this
Trail Making Test B
decreases, p = 0.038
the Trail Making Test A and B scores were significantly improved after placebo administration (p = 0.042 and 0.038, respectively)
PMID 31623400 · one of two readings recorded this
stress and anxiety levels
decreases
Our findings suggest that supplementation of 200-400 mg/day of L-THE may assist in the reduction of stress and anxiety in people exposed to stressful conditions
PMID 31758301 · one of two readings recorded this
continuous finger-cuff systolic and diastolic blood pressure, area under the curve over 90 minutes after eating sorbet with or without 200 mg L-theanine; heart rate and HRV
no effect, systolic BP AUC, between-group, entire 90 minute period, p = 0.839
Not recorded as a finding: a node exists but the paper states a different instrument or population
For systolic BP, between-group analysis for AUC did not demonstrate any significant effects for the entire 90 minute period (median; 1323 mmHg, 25th; 1157 mmHg, 75th; 1462 mmHg, p = 0.839).
PMID 32210015 · one of two readings recorded this
Diastolic blood pressure AUC 0-90 min
no effect, p = 0.922, n = 11
For diastolic BP, between-group AUC analysis showed no significant differences during the entirety of the 90 minutes amongst either of the conditions (median; 1323 mmHg, 25th; 1157 mmHg, 75th; 1462 mmHg, p = 0.922)
PMID 32210015 · one of two readings recorded this
Heart rate AUC 0-90 min
no effect, p = 0.996, n = 11
Between-group AUC analysis showed no significant differences during the entire 90 minutes between either of the conditions (median; 1325, 25th; 1222, 75th; 1385, p = 0.996)
PMID 32210015 · one of two readings recorded this
Heart rate, within-group analysis
modulates, p = 0.003, n = 11
within-group analysis showed significant differences within the baseline group (p = 0.003) as well as within the ms-L-THE group (p = 0.066)
PMID 32210015 · one of two readings recorded this